Matinas Interest Income from 2010 to 2026
| MTNB Stock | USD 0.59 0 0.68% |
Interest Income | First Reported 2010-12-31 | Previous Quarter 622.5 K | Current Value 653.6 K | Quarterly Volatility 280.5 K |
Check Matinas BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Matinas BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 17.7 M, as well as many indicators such as Price To Sales Ratio of 36.64, Dividend Yield of 4.34 or PTB Ratio of 0.36. Matinas financial statements analysis is a perfect complement when working with Matinas BioPharma Valuation or Volatility modules.
Matinas | Interest Income | Build AI portfolio with Matinas Stock |
Latest Matinas BioPharma's Interest Income Growth Pattern
Below is the plot of the Interest Income of Matinas BioPharma Holdings over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Matinas BioPharma's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Matinas BioPharma's overall financial position and show how it may be relating to other accounts over time.
| Interest Income | 10 Years Trend |
|
Interest Income |
| Timeline |
Matinas Interest Income Regression Statistics
| Arithmetic Mean | 278,634 | |
| Geometric Mean | 101,100 | |
| Coefficient Of Variation | 100.68 | |
| Mean Deviation | 269,981 | |
| Median | 56,550 | |
| Standard Deviation | 280,534 | |
| Sample Variance | 78.7B | |
| Range | 637.1K | |
| R-Value | 0.89 | |
| Mean Square Error | 16.9B | |
| R-Squared | 0.80 | |
| Slope | 49,635 | |
| Total Sum of Squares | 1.3T |
Matinas Interest Income History
About Matinas BioPharma Financial Statements
Matinas BioPharma stakeholders use historical fundamental indicators, such as Matinas BioPharma's Interest Income, to determine how well the company is positioned to perform in the future. Although Matinas BioPharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Matinas BioPharma's assets and liabilities are reflected in the revenues and expenses on Matinas BioPharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Matinas BioPharma Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Interest Income | 622.5 K | 653.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out the analysis of Matinas BioPharma Correlation against competitors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Matinas BioPharma. If investors know Matinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Matinas BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Matinas BioPharma is measured differently than its book value, which is the value of Matinas that is recorded on the company's balance sheet. Investors also form their own opinion of Matinas BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Matinas BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Matinas BioPharma's market value can be influenced by many factors that don't directly affect Matinas BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Matinas BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Matinas BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Matinas BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.